CapLaw-2026-72

On 20 July 2026, PolyPeptide Group AG (SIX: PPGN), a specialized global Contract Development & Manufacturing Organization (CDMO) for peptide-based active pharmaceutical ingredients, and Samsung Biologics Co., Ltd. announced that they have entered into a transaction agreement under which Samsung Biologics agreed to make an all-cash public tender offer to acquire all publicly held registered shares of PolyPeptide for CHF 44.31 per share. The offer values PolyPeptide‘s equity at approximately CHF 1.46 billion. Samsung Biologics published its pre-announcement of the offer today. PolyPeptide‘s largest individual shareholder, owning a stake of approximately 55.65% (excluding treasury shares), has committed to tender all…